Patent EP0199457A1 successfully refreshed from Google Patents.
US3884969A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel prostaglandins
Assignee: Wyeth Holdings LLC
•
Filing: 1973-04-20
•
Granted: 1975-05-20
•
Expires: 1993-04-20
Abstract
Abstract This disclosure describes novel 15-hydroxy prostanoic acid derivatives having anti-ulcer bronchodilator, and hypotensive activity.
Inventors
- 👤 Robert Eugene Schaub
- 👤 Martin Joseph Weiss
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 18:27
CPC Classifications
C; C07; C07D; C07D307/00; C07D307/77; C07D307/93; C07D307/935; C07C; C07C33/00; C07C33/40; C07C33/44; C07C405/00; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/54; C07F9/5407
Claims Analysis
Total Claims: 56
Claim 1
Independent Claim
9 words
1-9-OXO-15-HYDROXY-16METHYL-18,20-ETHANO-13-TRANSPROSTENOIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE CATIONIC SALTS THEREOF.
Claim 2
Dependent Claim
9 words
1-9-OXO-15-HYDROXY-16METHYL-18,20-ETHANO-13-TRANSPROSTENOIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE CATIONIC SALTS THEREOF.
Claim 3
Dependent Claim
9 words
d1-9-Oxo-15-hydroxy-16-methyl-18,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 4
Dependent Claim
9 words
d1-9-Oxo-15-hydroxy-16-methyl-18,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 5
Dependent Claim
10 words
1-9-Oxo-15-hydroxy-16,20-methano-13-trans, 18-prostadienoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 6
Dependent Claim
10 words
1-9-Oxo-15-hydroxy-16,20-methano-13-trans, 18-prostadienoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 7
Dependent Claim
10 words
d1-9-Oxo-15-hydroxy-16,20-methano-13-trans, 18-prostadienoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 8
Dependent Claim
10 words
d1-9-Oxo-15-hydroxy-16,20-methano-13-trans, 18-prostadienoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 9
Dependent Claim
9 words
1-9-Oxo-10a-homo-15-hydroxy-17,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 10
Dependent Claim
9 words
1-9-Oxo-10a-homo-15-hydroxy-17,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 11
Dependent Claim
9 words
d1-9-Oxo-10a-homo-15-hydroxy-17,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 12
Dependent Claim
9 words
d1-9-Oxo-10a-homo-15-hydroxy-17,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 13
Dependent Claim
9 words
1-9-Oxo-2-methyl-15-hydroxy-16-ethyl-19,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 14
Dependent Claim
9 words
1-9-Oxo-2-methyl-15-hydroxy-16-ethyl-19,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 15
Dependent Claim
10 words
d1-9-Oxo-2-methyl-15-hydroxy-16-ethyl-19,20-(1,3-propano)-13-trans -prostenoic acid and the pharmaceutically acceptable cathionic salts thereof.
Claim 16
Dependent Claim
10 words
d1-9-Oxo-2-methyl-15-hydroxy-16-ethyl-19,20-(1,3-propano)-13-trans -prostenoic acid and the pharmaceutically acceptable cathionic salts thereof.
Claim 17
Dependent Claim
9 words
1-9-Oxo-3,3-dimethyl-15-hydroxy-16,20-methano-13-trans-prostenoic acid and the pharmaceutically aCceptable cationic salts thereof.
Claim 18
Dependent Claim
9 words
1-9-Oxo-3,3-dimethyl-15-hydroxy-16,20-methano-13-trans-prostenoic acid and the pharmaceutically aCceptable cationic salts thereof.
Claim 19
Dependent Claim
9 words
d1-9-Oxo-3,3-dimethyl-15-hydroxy-16,20-methano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 20
Dependent Claim
9 words
d1-9-Oxo-3,3-dimethyl-15-hydroxy-16,20-methano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 21
Dependent Claim
9 words
1-9-Oxo-3-oxa-15-hydroxy-16,19-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 22
Dependent Claim
9 words
1-9-Oxo-3-oxa-15-hydroxy-16,19-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 23
Dependent Claim
9 words
d1-9-Oxo-3-oxa-15-hydroxy-16,19-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 24
Dependent Claim
9 words
d1-9-Oxo-3-oxa-15-hydroxy-16,19-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 25
Dependent Claim
9 words
1-9-Oxo-3-oxa-15-hydroxy-16-ethyl-19,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 26
Dependent Claim
9 words
1-9-Oxo-3-oxa-15-hydroxy-16-ethyl-19,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 27
Dependent Claim
9 words
d1-9-Oxo-3-oxa-15-hydroxy-16-ethyl-19,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 28
Dependent Claim
9 words
d1-9-Oxo-3-oxa-15-hydroxy-16-ethyl-19,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 29
Dependent Claim
9 words
1-9-Oxo-3-thia-15-hydroxy-16,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 30
Dependent Claim
9 words
1-9-Oxo-3-thia-15-hydroxy-16,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 31
Dependent Claim
9 words
d1-9-Oxo-3-thia-15-hydroxy-16,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 32
Dependent Claim
9 words
d1-9-Oxo-3-thia-15-hydroxy-16,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 33
Dependent Claim
9 words
1-9-Oxo-3-thia-15-hydroxy-16-methyl-18,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 34
Dependent Claim
9 words
1-9-Oxo-3-thia-15-hydroxy-16-methyl-18,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 35
Dependent Claim
9 words
d1-9-Oxo-3-thia-15-hydroxy-16-methyl-18,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 36
Dependent Claim
9 words
d1-9-Oxo-3-thia-15-hydroxy-16-methyl-18,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 37
Dependent Claim
9 words
1-9-Oxo-15-hydroxy-15-methyl-18,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 38
Dependent Claim
9 words
1-9-Oxo-15-hydroxy-15-methyl-18,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 39
Dependent Claim
9 words
d1-9-Oxo-15-hydroxy-15-methyl-18,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 40
Dependent Claim
9 words
d1-9-Oxo-15-hydroxy-15-methyl-18,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 41
Dependent Claim
9 words
1-9-Oxo-15-hydroxy-15-methyl-17,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 42
Dependent Claim
9 words
1-9-Oxo-15-hydroxy-15-methyl-17,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 43
Dependent Claim
9 words
d1-9-Oxo-15-hydroxy-15-methyl-17,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 44
Dependent Claim
9 words
d1-9-Oxo-15-hydroxy-15-methyl-17,20-(1,3-propano)-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 45
Dependent Claim
9 words
1-9-Oxo-3-thia-15-hydroxy-15-methyl-17,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 46
Dependent Claim
9 words
1-9-Oxo-3-thia-15-hydroxy-15-methyl-17,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 47
Dependent Claim
9 words
d1-9-Oxo-3-thia-15-hydroxy-15-methyl-17,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 48
Dependent Claim
9 words
d1-9-Oxo-3-thia-15-hydroxy-15-methyl-17,20-ethano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 49
Dependent Claim
2 words
1-Decyl 9-oxo-15-hydroxy-16-methyl-18,20-ethano-13-trans-prostenoate.
Claim 50
Dependent Claim
2 words
1-Decyl 9-oxo-15-hydroxy-16-methyl-18,20-ethano-13-trans-prostenoate.
Claim 51
Dependent Claim
2 words
d1-Decyl 9-oxo-15-hydroxy-16-methyl-18,20-ethano-13-trans-prostenoate.
Claim 52
Dependent Claim
2 words
d1-Decyl 9-oxo-15-hydroxy-16-methyl-18,20-ethano-13-trans-prostenoate.
Claim 53
Dependent Claim
9 words
1-9-Oxo-15-hydroxy-17,18-cis-methano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 54
Dependent Claim
9 words
1-9-Oxo-15-hydroxy-17,18-cis-methano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 55
Dependent Claim
10 words
d1-9-Oxo-15-hydroxy 17,18-cis-methano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
Claim 56
Dependent Claim
10 words
d1-9-Oxo-15-hydroxy 17,18-cis-methano-13-trans-prostenoic acid and the pharmaceutically acceptable cationic salts thereof.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1978-05-19 | 1978-11-18 | 1979-05-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1982-05-19 | 1982-11-18 | 1983-05-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1986-05-19 | 1986-11-18 | 1987-05-20 | $7700.00 | Window Closed / Lapsed |